Understanding CGRP and cardiovascular risk

14Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Increasing knowledge about the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has led to the development of antibodies against this peptide or its receptor. However, CGRP is widely expressed throughout the body, participating not only in pathophysiological conditions but also in several physiological processes and homeostatic responses during pathophysiological events. Therefore, in this chapter, the risks of long-term blockade of the CGRP pathway will be discussed, with focus on the cardiovascular system, as this peptide has been described to have a protective role during ischemic events, and migraine patients present a higher risk of stroke and myocardial infarction.

Cite

CITATION STYLE

APA

Rubio-Beltrán, E., & van den Brink, A. M. (2019). Understanding CGRP and cardiovascular risk. In Handbook of Experimental Pharmacology (Vol. 255, pp. 131–140). Springer New York LLC. https://doi.org/10.1007/164_2019_204

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free